Physiologic levels of extracellular PP i , which suppresses hydroxyapatite crystal growth, must be maintained by articular chondrocytes and resident cells in many othee tissues in order to prevent pathologic calcification. However, extracellular PP i rises in articular cartilage in direct association with aging. Matrix supersaturation with PP i stimulates chondrocalcinosis manifesting as calcium pyrophosphate dihydrate (CPPD) crystal deposition. Extracellular PP i levels are normally held in check by balances in PP i generation by nucleotide pyrophosphatase phosphodiesterase (NPP/NTPPPH) activity relative to PP i degradation by pyrophosphatases, by balance effects of cytokines and growth factors, and by transport of PP i from the cell interior involving the multiple-pass transmembrane protein ANK. But these mechanisms become dysrgulated in aging and osteoarthritic (OA) cartilage and extracellular PP i excess supervenes, mediated in large part by upregulated NPP1 and ANK expression in articular cartilage. Conversely, NPP1 and ANK deficiency states were recently linked to phenotypically similar forms of spontaneous soft tissue calcification with hydroxyapatite (HA). Here, we focus on recent advances in understanding of PP i metabolism and NPP1 and ANK function pertinent to the pathogenesis of pathologi matrix calcification in articular cartilage.
ABSTRACT
Physiologic levels of extracellular PP i , which suppresses hydroxyapatite crystal growth, must be maintained by articular chondrocytes and resident cells in many othee tissues in order to prevent pathologic calcification. However, extracellular PP i rises in articular cartilage in direct association with aging. Matrix supersaturation with PP i stimulates chondrocalcinosis manifesting as calcium pyrophosphate dihydrate (CPPD) crystal deposition. Extracellular PP i levels are normally held in check by balances in PP i generation by nucleotide pyrophosphatase phosphodiesterase (NPP/NTPPPH) activity relative to PP i degradation by pyrophosphatases, by balance effects of cytokines and growth factors, and by transport of PP i from the cell interior involving the multiple-pass transmembrane protein ANK. But these mechanisms become dysrgulated in aging and osteoarthritic (OA) cartilage and extracellular PP i excess supervenes, mediated in large part by upregulated NPP1 and ANK expression in articular cartilage. Conversely, NPP1 and ANK deficiency states were recently linked to phenotypically similar forms of spontaneous soft tissue calcification with hydroxyapatite (HA). Here, we focus on recent advances in understanding of PP i metabolism and NPP1 and ANK function pertinent to the pathogenesis of pathologi matrix calcification in articular cartilage.
INTRODUCTION
Supersaturation of certain solutes in body fluids may culminate in the extracellular deposition of distinct crystals and calculi and in dystrophic or organized matrix calcification. Pathologic calcification can manifest in the extracellular matrix of certain connective tissues such as the artery wall in subjects with atherosclerosis or chronic renal failure. Significantly, articular cartilage, unlike growth plate cartilage, is specialized to avoid the process of matrix calcification. But the matrix of articular hyaline cartilage, like that of fibrocartilaginous menisci, lends itself well to pathologic calcification, particularly in association with certain changes in matrix composition in aging and OA (1, 2). PP i is a potent inhibitor of the nucleation and propagation of basic calcium phosphate crystals such as HA (3). Concordantly, maintenance of physiologic extracellular PP i levels by chondrocytes and certain other cells serves to suppress calcification with HA, as illustrated in certain mouse models of deficient PP i generation and transport, as well as a variant of human infantile arterial calcification associated with periarticular calcification discussed below. But the relatively unique capacity of chondrocytes to produce copious amounts of extracellular PP i is double edged, as it is a major factor in promoting CPPD crystal deposition (Figure 1 ). Furthermore, excess PP i generation can promote HA crystal deposition by providing a source for increased P i generation via PP i hydrolysis by inorganic pyrophosphatase and alkaline phosphatase activities (Figure 1 ). Indeed, depending on cartilage ATP and PP i concentrations, and the level of activity of P i -generating ATPases and pyrophosphatases, CPPD and HA crystal formation may be jointly promoted in cartilage, an event that commonly occurs clinically in OA cartilage (1), as discussed further below.
PP i GENERATION AND DEGRADATION
PP i is comprised of two inorganic phosphate (P i ) molecules linked by a hydrolyzable high energy ester bond (Figure 2 ). Widely used in drug therapy for mineralization disorders is the class of synthetic, therapeutic compounds Factors driving pathologic calcification are indicated in green and physiologic factors suppressing calcification in red. Excess PP i generation in aging cartilages in idiopathic CPPD deposition disease of aging, and in OA cartilages, is mediated in part by marked increases in nucleoside triphosphate pyrophosphohydrolase (NTPPPH) activity, mediated in large part by the PC-1/NPP1 isoenzyme. In idiopathic chondrocalcinosis of aging and in OA, there are substantial increases in joint fluid PP i derived largely from cartilage. NPP1 not only directly induces elevated PP i but also matrix calcification by chondrocytes in vitro. Depending on extracellular availability of substrate PP i and the activity of pyrophosphatases, the availability of substrate ATP and the activity of ATPases, and other factors such as substantial local Mg ++ concentrations, HA crystal deposition, as opposed to CPPD deposition, may be stimulated. In this model, excess extracellular PP i also may result from heightened release of intracellular PP i via increased ANK expression in OA and abnormal ANK function in familial chondrocalcinosis, as well as from deficient activity of pyrophosphatases (such as tissuenonspecific alkaline phosphatase (TNAP) and possibly inorganic pyrophosphatase) in certain primary metabolic disorders. Also illustrated at the top of this schematic is the role in cartilage calcification in OA and aging of altered TGFβ expression and responsiveness, which drives PP i generation and release mediated via NPP1 and ANK, and diminished responsiveness to IGF-I, which normally suppresses elevation of chondrocyte extracellular PP i .
termed bisphosphonates (Figure 2) , have a carbon instead of an oxygen molecule separating two phosphate, thereby allowing these drugs to serve in part as nonhydrolyzable PP i analogues. Natural compounds similar in structure to PP i include the calcific crystallization inhibitor phosphocitrate (4) (Figure 2 ). Phosphocitrate is a synthetic product of citrate and ATP that is highly enriched in mitochondria. But some of the described effects of phosphocitrate on calcification may be mediated in part by citrate effects, and this review focuses on PP i .
PP i generation and disposal are finely balamced (3). Though a PP i synthase exists in primitive organisms, PP i does not appear to be synthesized de novo in mammalian cells, where PP i is formed either as a metabolic byproduct of numerous biochemical and biosynthetic reactions (3) or directly by pyrophosphohydrolysis of the phosphodiesterase I bond in purine and pyrimidine nucleoside triphosphates (NTPPPH activity) (EC 3.6.1.8) (5) . NTPPPH activity is a primary effect of two members of the Nucleotide Pyrophosphatase Phosphodiesterase (NPP) family (5, 6), PC-1/NPP1 and B10/NPP3 (3, 7, 8) . These ~130 kDa transmembrane ecto-enzymes form disulfide-bonded homodimers (5, 6) . Secreted NPP1 is generated at the plasma membrane via proteolysis and is the predominant circulating NPP1 in plasma (5, 9) .
In plasma, normal PP i concentrations are in the micromolar range, and urinary PP i excretion is substantial (3). Much of circulating PP i is believed to be released from the liver and taken up by bone (3). The extent and functional significance of PP i binding to plasma proteins are undefined.
Analogous to effects of not only inorganic phosphate (P i ) (10, 11) but also bisphosphonates (12, 13), intracellular and extracellular PP i appears to directly influence gene expression and cell functions, as discussed below. Hence, it is not surprising that specialized mechanisms exist for both PP i transport and PP i degradation, as well as generation of PP i by NTPPPH activity. Mammalian extramitochondrial mechanisms for PP i production, degradation, and transport were recently reviewed in depth (3). These mechanisms include PP i transport by ANK discussed below. They also include the essential action in mineralization of tissue-nonspecific alkaline phosphatase (TNAP), an ecto-enzyme that generates pro-mineralizing P i by not only ATPase activity but also by catalyzing PP i degradation at an alkaline pH optimum, exerting major effects on extracellular PP concentrations (14) (15) (16) . Recent comparative analyses of primary structures have revealed that alkaline phosphatases and the PDNP family of NTPPPH metalloenzymes share certain features that mediate enzyme activity (17, 18) It appears that a substantial fraction of intracellular PP i is generated in the mitochondria and intracellular and extracellular PP i concentrations are both under the regulation of mitochondrial energy metabolism (3, 19).
As reviewed recently (3), mitochondria carry out a complete catalytic cycle employing P i that results in the spontaneous synthesis of ATP and PP i . Intramitochondrial PP i also is under the control of calcium, a suppressor of mitochondrial matrix inorganic pyrophosphatase activity. . Structure of PP I is illustrated on the upper left, whereas the upper right depicts the structure of phosphocitrate, a naturally occurring phosphorylated polycarboxylic acid that is particularly abundant in mitochondria. Phosphocitrate also is released within the renal tubules and detectable in the urine. The structural framework for synthetic bisphosphonates is illustrated in the bottom panel, where the nature of the R2 side chain determines whether the agents are aminobisphosphonates or nonaminobisphosphonates, and modifies their functional properties. PP I , phosphocitrate, and bisphosphonates act not only to modulate crystallization inhibitor of hydroxyapatite (HA) but have other effects on cell function, as discussed in the text and reviewed elsewhere for bisphoshonates. For example, simple bisphosphonates that closely resemble PP i (e.g., clodronate, etidronate) can be metabolically incorporated into non-hydrolyzable ATP that accumulate intracellularly and modulate apoptosis. More potent, nitrogen-containing bisphosphonates (e.g., pamidronate, alendronate, risedronate, zoledronate) can act as analogues of isoprenoid diphosphate lipids, and thereby affect mevalonate pathway activity and can regulate activity of small GTP-binding proteins such as ras.
We established that mitochondrially-derived ATP is a major substrate for NTPPPH-mediated generation of both intracellular and extracellular PP i in the chondrocyte (19). NTPPPH ecto-enzyme-mediated PP i synthesis also takes place in the lumen of the endoplasmic reticulum, and likely also in the Golgi, where an active transport system exists to pump in ATP, as reviewed (3).
Extracellular PP i has been extensively studied in a pathophysiologic context in mammals with respect to inhibitory effects on hydroxyapatite nucleation and crystal growth (3). In lower organisms, PP i (like ATP) serves as a primordial "high-energy" compound, and PP i (or polyphosphates) are able to substitute for ATP under certain circumstances, such as in glycolysis-related reactions in harsh environments under conditions where respiration is attenuated (3). But functional effects of free intracellular PP i are not well understood in higher organisms and are likely underestimated. PP i can interact with and potentially modify the activity of certain ATPases and can modify iron transport, mitochondrial metabolism, protein phosphorylation, DNA replication, protein synthesis, and calcium release from mitochondrial stores (reviewed in reference 3).
PP i METABOLISM IN ARTICULAR CARTILAGE
In the pericellular matrix of aging and osteoarthritic (OA) cartilages, changes in chondrocyte differentiation and viability, alterations in matrix composition, and a dysregulated increase in chondrocyte extracellular PP i promote deposition of CPPD and/or basic calcium phosphate crystals including HA (1, 2, 20) ( Figure  1 ). Cartilage crystal deposition and crystal trafficking to the synovial membrane are believed to worsen the course of degenerative joint disease by promoting expression of inflammatory and cartilage-matrix-degrading genes by synovial lining cells, resident mononuclear phagocytes and chondrocytes, and by triggering inflammatory synovitis (21).
As cited above, physiologic levels of extracellular PP i must be maintained by chondrocytes to suppress matrix deposition of HA (Figure 1 ), apparently reflecting antagonistic effects of PP i and P i on mineralization. The balance between PP i and P i in mineralizing tissues is complex partly because extracellular PP i is a major source of P i generated by TNAP activity, and P i clearly promotes mineralization (14) (15) (16) . Cytokine and growth factor balance also appear to keep extracellular PP i levels in check. For example, in normal chondrocytes, TGFβ increases and IGF-I decreases extracellular PP i (1, 22). IGF-I also inhibits the capacity of TGFβ to induce elevated extracellular PP i (22, 23). The interplay between TGFβ and IGF-I on PP i metabolism is partly mediated by expression of the matrix protein Cartilage Intermediate Layer Protein-1 (CILP), an IGF-I inhibitor induced by TGFβ (23). Significantly, IL-1 and TNFα also decrease extracellular PPi and inhibit the capacity of TGFβ to induce elevated extracellular PP i (24). Extracellular PP i rises markedly in cartilage in direct association with aging and OA, and resultant matrix supersaturation with PP i can stimulate both CPPD and HA deposition (reviewed in 1, 3, 7). Physiologic chondrocyte PP i metabolism depends largely on the balance between PP i generation and degradation, on a normal capacity for PP i transport, and on normal chondrocyte responsiveness to growth factors. Interruption in these regulatory checks and balances appears to occur in aging and OA, under the influence of altered chondrocyte responsiveness to growth factors.
PP i GENERATION BY CHONDROCYTES
Chondrocytes produce PP i by a variety of biosynthetic reactions and by the action of the aforementioned NPP family isoenzymes that hydrolyze nucleoside triphosphates at the phosphodiester I bond by NTPPPH activity (7, 8) . Three NPP family ecto-enzymes with NTPPPH activity (NPP1-3) share disulfide-bonded homodimeric structures as exemplified by NPP1 (5, 6) . But up to half of extracellular PP i in skeletal cells and fibroblasts is generated by the activity of NPP1 (9, 25) , and NPP2 appears to act primarily as a lysophospholipase D (25a) and T-type ATPase rather than PP i -generating NTPPPH, whereas NPP3 appears to principally influence intracellular PP i in chondrocytes (7).
Osteoblasts and chondrocytes have particularly high levels of NTPPPH specific activity. Moreover, chondrocyte NTPPPH activity increases in direct condordance with cartilage PP i generation (to an average of double normal levels) in a donor age-dependent manner (3, 26), as illustrated again recently in both human knee meniscal cells (3, 7). The age-dependent increases in NTPPPH activity are directly linked to chondrocalcinosis (26). Synovial fluid levels of the NTPPPH substrate ATP also rise to approximately double control levels in idiopathic CPPD crystal deposition disease of aging (27). Furthermore, up-regulation of NPP1 but not the other NTPPPH isoenzymes is associated with crystal deposition by chondrocytic cells in situ and in vitro (7).
The ability of certain cartilage-expressed factors to modulate chondrocyte extracellular PP i levels is transduced in part by changes in NTPPPH activity and the availability to NTPPPH of substrate ATP (3, 27). In this regard, TGFβ increases cartilage NTPPPH activity and extracellular PP i levels in a manner that directly correlates with donor age (7, 28) . The TGFβ-stimulated cellular program for chondrocyte extracellular PP i elevation includes substantial increases in ATP generation (29) , increased transcription of NPP1 (24) and stimulation of NPP1 movement to the plasma membrane (where NPP1 remains an ecto-enzyme) (8) , in a manner dependent on the cytosolic tail dileucine motif of NPP1 (30) . The ability of IL-1 and TNF to suppress extracellular PP i correlates with suppression of NPP1 expression and NTPPPH specific activity in chondrocytes (24). The mechanism by which IGF-I suppresses extracellular PP i may involve suppression of expression of the PP i transporter ANK (31) discussed below.
ANK, NPP1, AND PP i METABOLISM IN MATRIX CALCIFICATION
Osteoblasts, chondrocytes, and certain other cells release intracellular PP i by a membrane transport system involving ANK, a 54 kDa polypeptide with a predicted multiple-pass transmembrane configuration (32) . ANK expression is up-regulated in OA and chondrocalcinotic cartilages (31, 33) . A truncation mutation of the C-terminal cytosolic domain, the last of six putative cytosolic domains in ANK, occurs naturally in ank/ank mice, and this mutation is associated with elevation of intracellular PP i and a decrease in extracellular PP i (25, 32, 33) . Wild type ANK decreases intracellular PP i and elevates extracellular PP i concentrations in normal cells (32, 33) . The ank mutant lacking the C-terminal (sixth) cytosolic domain appears to have totally incapacitated ANK PP i transport activity (32) .
ANK and NPP1 appear to co-dependently function to raise extracellular PP i (25), suggesting that ANK moves the specific fraction of intracellular PP i generated by NPP1. Consistent with this model is the remarkable similarity in the consequences of deficient ANK and PC-1 function in vivo. Both ank/ank mice and NPP1 deficient mice develop a progressive matrix hypermineralizing phenotype that with increasing age comes to include OA and extensive articular cartilage HA deposits, spinal ligament hyperostosis, arterial calcification, and ossific fusion of peripheral joints (15, 16, 25, 32, 34) . Deficiency of NPP1 also produces certain comparable phenotypic features in humans (9) and is the predominant cause of human arterial calcification of infancy, a frequently lethal disease characterized by widespread artery media calcification and common periarticular HA deposits (35, 36) . Mutations widely spread through the NPP1 extracellular domain can impair catalytic activity (35, 36) .
Unlike cultured cells of ank/ank mice, NPP1-deficient cells demonstrate low intracellular as well as extracellular PP i levels (25). Thus, the common basis for the remarkably similar hypermineralizing phenotypes seen in ank/ank mice and in NPP1 null mice (and the hypercalcification seen in human NPP1 deficiency) clearly rests in depression of extracellular PP i .
NPP1 AND MATRIX VESICLES (MVS) IN CALCIFICATION
Chondrocyte-derived and osteoblast-derived membrane-limited secretory bodies termed matrix vesicles (MVs) have the capacity to provide a sheltered environment for initiation of HA and CPPD crystal formation in a manner modulated by the concentration of PP i and other constituents associated with MVs (37). NPP1 is clearly the principal NTPPPH associated chondrocytederived and osteoblast-derived MVs, as confirmed recently by analyses of NPP1-/-mouse cells (30) . Significantly, chondrocyte differentiation and a variety of calciotropic hormones and cytokines (including 1,25 dihydroxyvitamin D3, TGFβ and IL-1) can regulate the NPP1 content, NTPPPH and alkaline phosphatase activities, PP i content, and other compositional features of MVs (37-39). We have not seen concentrated ANK localization in MVs (16) .
Chondrocyte maturation to hypertrophy is associated with heightened PP i generation and shedding of mineralization-competent matrix vesicles (MVs) (38) . Chondrocytic MVs, like osteoblast-derived MVs are enriched markedly in NPP1 (7, 14, 15, 30, 40) as well as TNAP relative to the plasma membrane, and the catalytic domains of NPP1 and TNAP are predominantly exposed at the external face of MVs. NPP1 and TNAP exert critically important, mutually anatagonistic regulatory effects on HA deposition in vivo, exerted partly at the level of the MV (14, 15) . In contrast, TNAP and B10/NPP3, which is predominantly localized intracellularly in mineralizing cells, do not appear to be mutually antagonistic in PP i metabolism (14) . As such, the mechanisms underlying colocalization of TNAP and NPP1 at the plasma membrane and in MVs are of substantial interest.
Excess NPP1 expression, but not excess NPP2 or NPP3 expression, was associated with increased meniscal cell apoptosis (presumably mediated by PP i excess) (40) . Concurrently, we observed the release of functionally altered MVs in chondrocytes expressing excess NPP1 (40) . Specifically, such MVs, which presumably were enriched in apoptotic bodies, contained increased amounts of the calcium-binding protein annexin V and precipitated more calcium in both an ATP-dependent and ATP-independent manner (40).
EFFECTS OF PP i ON OSTEOPONTIN EXPRESSION
Recently, it has been recognized that P i regulates the expression of certain genes in skeletal cells (41) . These effects include stimulation by P i (mediated by plasma membrane sodium-phosphate co-transport) of expression of osteopontin, an inhibitor of HA crystal deposition and promoter of mineral resorption (41). Significantly, exogenous PP i promotes osteopontin and MMP-13 expression (16, 25, 33) . Hence, altered PP i generation by skeletal cells likely modulates chondrocyte differentiation partly by regulating gene expression.
We observed that a deficiency state for extracellular PP i in NPP1-/-and ank/ank mice was associated with deficient osteopontin expression, and osteopontin deficiency was a critical effect facilititating increased calcification in vitro (25). This represesents the remarkable case of a deficiency of one HA crystal growth inhibitor inducing a deficiency of a second HA crystal growth inhibitor. Because osteopontin knockout mice have only mild changes in bone mineral crystal size, as opposed to the marked phenotypic abnormalities in extracellular PP i -deficient mice, PP i clearly is more elevated than osteopontin in the physiologic hierarachy of HA crystal growth inhibitors.
MODEL FOR DYSREGULATED PP i METABOLISM IN AGING AND OA ARTICULAR CARTILAGES
We have demonstrated that chondrocyte mitochondrial dysfunction associated with spontaneous Hartley guinea pig knee OA promtes ATP depletion, and that increased NTPPPH activity and extracellular PP i develop concurrent with the ATP-depleted state (19). Hence, increased ATP-scavenging by energy-depleted chondrocytes likely drives extracellular PPi excess in OA and aging chondrocalcinotic cartilages. In addition, in the model presented in Figure 1 , PP i metabolism becomes dysregulated in part via increased PP i generation in response to TGFβ (8) , mediated in large part by upregulation of ANK and NPP1 and their synergistic effects. In this model, PP i metabolism becomes dysregulated in aging cartilage in part via lessening of the inhibitory effect of IGF-I on extracellular PP i . Articular chondrocytes in aging cartilages demonstrate altered IGF-I responsiveness (42) , and in OA, the ability of IGF-I to stimulate and maintain normal chondrocyte differentiation appears to be diminished (43) . The IGF-I hyporesponsiveness in OA appears to be multifactorial (42, 44) . Increased levels of the IGFBPs 2, 3, 4, and altered IGFBP complex formation with IGF-I and the acid-labile subunit (ALS) (45) could play a role, as IGF-I receptor levels do not decrease in OA chondrocytes (46). The capacity of NO to suppress ligandinduced phosphorylation of the IGF-I receptor (44) and to inhibit proteoglycans synthesis (47) also may be significant modulators of IGF-I action in OA. It appears that one of the consequences of increased CILP-1 expression in aging cartilage is interference with the regulatory effects of IGF-I on PP i metabolism, thereby promoting increased extracellular PP i and CPPD crystal deposition.
DYSREGULATED ARTICULAR PP i METABOLISM AND CPPD CRYSTAL DEPOSITION DISEASE IN PRIMARY METABOLIC DISORDERS
Hypophosphatasia due to TNAP deficiency states, hypomagnesemic conditions (including the Gitelman's variant of Bartter's Syndrome), hemochromatosis, and hyperparathyroidism are linked to secondary CPPD crystal deposition disease (48) . Increased joint fluid PP i levels in each of these conditions indicates a shared theme of cartilage PP i excess (49) , likely mediated by effects of magnesium, iron, copper, and calcium on NPP1 catalytic activity and on pyrophosphatase activity.
ANKH MUTATIONS IN FAMILIAL CPPD CRYSTAL DEPOSITION DISEASE
Familial chondrocalcinosis is clinically heterogeneous (50) . Two major chromosomal linkages, 8q and 5p, have been identified in studies of familial CPPD deposition disease (50) . CCAL1 is the designation for the linkage with chromosome 8q of both early-onset OA and chondrocalcinosis in a New England family (51) . Chromosome 5p-linked chondrocalcinosis (CCAL2) is broadly distributed and has been studied in greater detail than 8q chondrocalcinosis (52-57, 57a) , with linkage to the ANKH gene now well-established. A search for ANKH gene mutation in 95 subjects with sporadic chondrocalcinosis also uncovered a unique mutation in one subject (56) . A subset of ~4% of severe human "idiopathic" chondrocalcinosis of aging has recently been linked to homozygosity for an ANKH promoter mutation that promotes increased ANKH expression (58).
Modeling of the PP i channeling function of human ANK has posited 10 or 12 membrane-spanning domains in ANK with an alternating inside/out orientation (32) and with a central channel to accommodate the passage of PP i (59) (Figure 3 ). Mutations at different locations in mouse ANK and in ANKH can affect function and the skeleton in a manner including autosomal dominant chondrocalcinosis (56, 57) , the phenotype of ank/ank mice (32) , and other abnormalities (59, 60) (Figure 3) . Clinical heterogeneity even for chondrocalcinosis associated with human ANK mutations (56, 57) suggests differing functional effects of ANK mediated by specific regions of the molecule.
In one form of 5p familial chondrocalcinosis, subtle "gain of function" of intrinsic ANKH PP i channeling activity, putatively via extension of the N-terminal domain by 4 amino acids, appears to lead to chronic, low-grade chondrocyte "PP i leakiness", thereby putatively causing matrix supersaturation with PP I , CPPD crystal deposition (56, 57) . However, not all ANKH mutants linked to familial chondrocalcinos directly raise extracellular PP i (58) . For example, marked intracellular PP i elevation was described in cell lines from the French chromosome 5p familial chondrocalcinosis kindred (61, 62) . With respect to chondrocalcinosis in OA and aging, ANKH expression is highly regulated, and secondary alterations in chondrocyte expression of not only wild type ANKH but also NPP1 likely drive PP i supersaturation in cartilage in idiopathic/sporadic and OA-associated CPPD crystal deposition disease.
Last, mutations clustered in the fifth cytosolic domain of the human ANK homologue ANKH encoding for single amino acid deletions or nonconservative amino acid substitutions were recently linked to a human autosomal dominant disease, Craniometaphyseal Dysplasia (CMD), in multiple families (59, 60) (Figure 3) . CMD features progressive thickening and increased mineral density of craniofacial bones ("mask facies") and abnormally developed (i.e., hypertrophic and flared) metaphyses of long bones (59, 60) . A theoretical model has been proposed in which enhanced PP i "leakiness" through the central pore of the channel is a factor in CMD pathogenesis (59) . However, there is no proof of dysregulated PP i metabolism in CMD and the disease may reflect abnormalities in bone resorption related to an undefined abnormality in ANKH function or an aberrant locus for ANKH PP i transport function.
PERSPECTIVE
Studies of extracellular PP i deficiency states in humans and mice have revealed the profound physiologic inhibitory role of PP i in extracellular matrix calcification in articular cartilage, spinal ligaments, synovium, and arteries. Since the discovery more than 3 decades ago of severalfold increased joint fluid PP i in OA and even more markedly increased joint fluid PP i in chondrocalcinosis (63) , and more than 20 years removed from the first observations that normal chondrocytes robustly produce extracellular PP i (64) , it also has become clear that PP i functions beyond a substrate regulating matrix deposition of HA and CPPD crystals. Toxic effects of extracellular PP i on chondrocyte viability and the capacity of PP i to modulate gene expression and differentiation indicate far-reaching effects of PP i on cell function that modulate physiologic and pathologic calcification, and underscore the appropriateness of the term "pyrophosphate arthropathy" to describe CPPDassociated chondrocalcinosis. Last, molecular characterization of effects of ANK/ANKH and NPP1 on mineralization and specific genetic linkages of ANKH and NPP1 with human diseases have provided rational targets for novel therapeutics for specific calcification disorders.
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